Beckman Coulter claims its DxI 9000 Access Immunoassay Analyser is the most productive immunoassay analyser per footprint – boasting up to 215 tests per hour per square meter (tests/hr/m2), with no daily maintenance.
The platform has been independently verified to perform at the European Federation of Clinical Chemistry and Laboratory Medicine (EFLM) optimal level. At the same time, the novel Lumi-Phos PRO Substrate has shown the capability to develop increasingly sensitive and clinically relevant assays, ensuring the system is able to meet the healthcare needs of tomorrow.
ZeroDaily Maintenance is one of the DxI 9000’s embedded innovations, which Beta users confirmed reduced annual maintenance routines by up to 96%. It also features PrecisionVision Technology tube identification, cap detection, tip check, sample aspiration, and delivery, residual wash volume, and substrate volume. Each check reduces the risk of reporting flawed data and increases system reliability and reproducibility.
Beckman Coulter’s newly designed remote service and diagnostics solution, DxS IntelliServe, connects with DxI 9000 Analysers to monitor data and error trends – enabling timely, proactive system service when needed. DxS IntelliServe also identifies service experts to resolve issues with real-time monitoring, remote operation, and troubleshooting. Remote update capabilities and proactive scheduling ensure systems run on the most up-to-date software, reducing unplanned workflow interruptions or downtime.
Julie Sawyer Montgomery, President, Beckman Coulter Diagnostics, said: “The DxI 9000 Access Immunoassay Analyser sets new expectations for immunoassay testing operational performance and ability to develop and sustain improved assay sensitivity to meet tomorrow’s analytical needs. Those in the laboratory will treasure ZeroDaily Maintenance to save them time, PrecisionVision Technology to safeguard against flawed data reports, and IntelliServe to maximise system uptime. At the same time, clinical researchers are excited about the DxI 9000 Analyser’s ability to keep pace with increasingly sensitive testing requirements as healthcare providers and pharmaceutical companies take aim at ever more challenging diseases. An inspiring feat of technology, the DxI 9000 Analyser is a comprehensive healthcare innovation.”
Dr. Pamela Christudoss, Professor and Head, Department of Clinical Biochemistry, Christian Medical College Vellore, India noted, said: “Like clinical laboratories worldwide, we are running more tests than any time in our history. The innovations packed into the DxI 9000 Analyzer will enable labs across the globe to improve their throughput rates and turnaround times with world-class precision. In particular, the team loved the un-paralleled Zero Daily Maintenance especially for a platform that runs 450 tests per hour.”
Mr. Ray Divilley, Chief Medical Officer, Mayo University Hospital, Ireland, added: “With the DxI 9000, Beckman Coulter has successfully produced a platform that addresses today’s laboratories needs for speed, accuracy, and reliability. Based on our use and evaluation of the system in our lab, we were able to get actionable results back quicker to doctors and ultimately patients as they consider treatment options.”
Find more information on the DxI 9000 Analyser on the Beckman Coulter website.
